Equities

BrightPath Biotherapeutics Co Ltd

4594:TYO

BrightPath Biotherapeutics Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)60.00
  • Today's Change0.00 / 0.00%
  • Shares traded88.10k
  • 1 Year change-57.75%
  • Beta1.2309
Data delayed at least 20 minutes, as of May 01 2024 03:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.

  • Revenue in JPY (TTM)118.00k
  • Net income in JPY-1.21bn
  • Incorporated2003
  • Employees32.00
  • Location
    BrightPath Biotherapeutics Co Ltd7F, Kojimachi Central Bldg2-2-4, Koji-machiCHIYODA-KU 102-0083JapanJPN
  • Phone+81 444403939
  • Fax+81 942386564
  • Websitehttps://www.brightpathbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ribomic Inc62.64m-979.09m2.95bn25.00--0.8168--47.16-27.45-27.451.76100.390.0144--1.222,505,440.00-22.56-32.10-24.05-33.30-----1,563.14-1,688.5018.53--0.00---18.470.38091.88--10.04--
Muromachi Chemicals Inc6.12bn216.69m2.99bn205.0013.661.388.510.488453.4553.451,503.34527.871.203.833.7529,862,370.004.23--6.84--28.31--3.54--1.4526.200.4483--10.74---43.83------
Atect Corp3.20bn114.29m3.01bn96.0026.231.436.530.940125.8525.85723.76474.920.57133.226.8533,330,020.002.042.032.832.7844.6847.693.573.840.7119--0.54629.40-4.032.10-6.3714.01-23.310.00
D.Western Therapeutics Institute Inc428.36m-812.41m3.37bn21.00--2.64--7.88-25.45-25.4513.4839.830.16070.43892.9820,398,290.00-31.09-13.06-33.75-14.3691.4494.29-193.39-72.5110.57--0.4089---4.407.90-89.07--7.08--
Kringle Pharma Inc70.58m-865.79m3.55bn13.00--1.45--50.28-158.59-158.5912.88374.930.024--0.73085,428,846.00-29.38-19.00-30.70-20.23-----1,226.76-156.5126.45-1,190.330.00---82.33---157.41------
OncoTherapy Science, Inc.901.22m-1.19bn3.70bn60.00--5.64--4.11-5.77-5.774.363.010.75895.3115.7415,020,330.00-100.44-50.21-132.58-55.41-9.03---132.35-331.973.29-258.180.00---1.6339.9756.50---57.92--
FunPep Co Ltd530.00k-933.42m3.80bn15.00--1.54--7,164.69-40.11-40.110.022594.970.0002----35,333.33-34.04-27.10-35.68-28.75-----176,116.20-815.8225.95-1,765.730.00---50.33-72.8020.39---13.14--
Human Metabolome Technologies Inc1.32bn282.64m3.87bn57.0013.702.1910.622.9347.8347.83223.67299.170.630214.234.7423,186,330.0013.48--16.73--65.03--21.39--4.27151.900.1103--6.21--6.71------
Kubota Pharmaceutical Holdings Co Ltd39.89m-1.49bn3.94bn12.00--1.48--98.80-26.80-26.800.717547.210.01070.531714.773,323,917.00-40.06-36.51-43.86-39.4770.48---3,734.55-13,528.8710.01--0.0512--383.24--26.11--24.38--
BrightPath Biotherapeutics Co Ltd118.00k-1.21bn4.17bn32.00--4.95--35,370.65-19.27-19.270.001911.920.00007--0.04233,687.50-71.34-42.65-89.42-44.49-433.0557.16-1,028,827.00-4,430.66---875.450.3929---65.73-56.89-0.0971---56.39--
Perseus Proteomics Inc96.22m-1.12bn4.21bn24.00--2.62--43.71-95.57-95.578.18131.490.04241.8211.224,009,083.00-49.52-33.51-51.65-34.9589.0193.09-1,168.66-470.6317.58--0.00--30.96-20.89-31.38--228.18--
Immuno-Biological Laboratories Co., Ltd.788.12m-192.71m4.36bn60.00--3.97--5.53-20.69-20.6984.62118.020.51440.87883.7813,135,280.00-12.58-15.11-14.85-17.6162.0656.66-24.45-50.043.490.4940.1774--22.710.9405-11.97------
Renascience Inc191.32m-331.66m4.41bn3.00--2.69--23.06-26.09-26.0915.05129.220.0851----63,772,000.00-14.74---15.49--85.75---173.36------0.1782---27.84---32.05------
MEDRx Co Ltd29.53m-932.90m4.64bn22.00--2.29--157.18-27.24-27.240.849250.170.01710.26061.221,342,455.00-54.07-58.15-58.45-62.2391.8795.70-3,158.72-1,526.1717.75--0.00---50.3528.6016.04---55.29--
Solasia Pharma KK617.00m-1.11bn5.02bn24.00--2.41--8.13-6.61-6.613.6710.780.23014.101.9325,708,330.00-41.51-48.57-47.74-58.8354.7871.01-180.39-300.892.91--0.031---43.5014.1856.36------
Kidswell Bio Corp2.62bn-1.21bn5.30bn41.00--3.62--2.02-37.72-37.7277.5637.570.55831.264.0063,807,830.00-25.82-58.77-36.65-77.4450.3059.87-46.25-139.311.86-21.980.6118--76.9221.24-22.83------
Data as of May 01 2024. Currency figures normalised to BrightPath Biotherapeutics Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

0.51%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 04 Apr 2024328.00k0.47%
SPARX Asset Management Co., Ltd.as of 10 Mar 202233.30k0.05%
Data from 29 Dec 2023 - 19 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.